Salesforce Primed To Benefit From AI Product Prioritization And Vendor Consolidation: Oppenheimer Analyst
Portfolio Pulse from Nabaparna Bhattacharya
Oppenheimer analyst Brian Schwartz reiterated an Outperform rating on Salesforce (NYSE:CRM) with a price target of $235. He believes the company is well positioned to benefit from vendor consolidation trends, AI product prioritization, and improving business efficiency. Salesforce is also poised to gain from margin growth, increased multi-cloud adoption, and success with verticalized solutions.
June 14, 2023 | 6:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Brian Schwartz reiterated an Outperform rating on Salesforce with a price target of $235, citing the company's potential to benefit from vendor consolidation, AI product prioritization, and improving business efficiency.
The analyst's positive outlook on Salesforce is based on the company's potential to benefit from various factors such as vendor consolidation trends, AI product prioritization, improving business efficiency, and the ability to enter new markets. These factors are likely to result in upward margin and cash flow revisions beyond the current consensus, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100